AlmegaPL® decreased triglycerides by 14%, which is 4 times the response expected from fish oil.HOUSTON, Feb. 15, 2024 /PRNewswire/ -- Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) by up to 25%.1,2  'This marks the second clinical trial endorsing the use of AlmegaPL® algal lecithin to support cardiovascular health in a generally healthy population,' says Dr.

AlmegaPL®将甘油三酯降低了14%，是鱼油预期反应的4倍。休斯顿，2024年2月15日/PRNewswire/-Qualitas Health，LLC（dba iwi life）一项新的临床试验结果表明，微藻衍生的AlmegaPL®是iwi life™生产的基础成分，可提供临床相关结果，可将甘油三酯和残余胆固醇（如极低密度脂蛋白（VLDL）和中密度脂蛋白（IDL））降低14%“这标志着第二次临床试验支持使用AlmegaPL®藻类卵磷脂来支持一般健康人群的心血管健康，”Dr。

Eneko Ganuza, a principal investigator who led the research..

领导这项研究的首席研究员Eneko Ganuza。。

Continue Reading

继续阅读

The new clinical trial led by Dr. Ganuza and sponsored by Qualitas Health was initiated to uncover just how effective an over-the-counter supplement can be in supporting cardiovascular health in the real-world population. The findings support existing beliefs that EPA-only omega-3s like AlmegaPL® could provide greater cardiovascular benefits when compared to traditional sources of omega-3s like fish and krill oil that contain both EPA and DHA..

由Ganuza博士领导并由Qualitas Health赞助的新临床试验旨在揭示非处方补充剂在支持现实世界人群心血管健康方面的有效性。这些发现支持了现有的观点，即与传统的含有EPA和DHA的ω-3脂肪酸来源（如鱼和磷虾油）相比，仅含EPA的ω-3脂肪酸（如AlmegaPL®）可以提供更大的心血管益处。。

AlmegaPL® decreased triglycerides by 14%, which is 4 times the response expected from fish oil.

AlmegaPL®将甘油三酯降低了14%，是鱼油预期反应的4倍。

Post this

发布此

According to the World Health Organization, cardiovascular disease (CVD) continues to be the leading cause of death globally, with dietary factors, including inadequate intake of long-chain n-3 polyunsaturated fatty acids —specifically EPA and DHA—estimated to contribute to approximately half of all CVD- related deaths annually.3,4 With 95% of the U.S.

根据世界卫生组织的数据，心血管疾病（CVD）仍然是全球死亡的主要原因，饮食因素包括长链n-3多不饱和脂肪酸（特别是EPA和DHA）的摄入不足，估计每年约占所有CVD相关死亡人数的一半。3,4占美国95%。

population failing to consume an adequate amount of omega-3s, interest around DHA and EPA treatment has grown, launching a growing debate around their subsequent roles in cardiovascular support.5.

由于没有摄入足够量的ω-3脂肪酸，人们对DHA和EPA治疗的兴趣日益浓厚，围绕其在心血管支持中的后续作用引发了越来越多的争论。

In the cohort study, AlmegaPL® delivered in the form of the iwi life 'Heart' supplement was clinically shown to decrease triglycerides by 14%, which is 4 times the response expected from other omega-3 sources.1 'While triglyceride levels within the normal range are typically beyond the scope of clinical intervention, they still retain a residual heart health risk,' states Dr.

在队列研究中，临床证明，以iwi life'Heart'补充剂形式提供的AlmegaPL®可将甘油三酯降低14%，这是其他ω-3来源预期反应的4倍。1“虽然甘油三酯水平在正常范围内通常超出临床干预范围，但它们仍然保留了残留的心脏健康风险，”Dr。

Ganuza. 'The study's significance is underscored by its execution within a real-world population, predominantly normolipidemic supplement consumers. This highlights the use of naturally sourced AlmegaPL® algal oil as an over-the-counter supplement to help support cardiovascular health in the general healthy population.'AlmegaPL® uses a proprietary strain of omega-3 fatty acid extracted from the photoautotrophic microalgae Nannochloropsis, which is now clinically confirmed by two independent studies to decrease remnant cholesterol by up to 25 %.1,2 Neither study resulted in an increase in LDL cholesterol, which is a unique benefit of EPA-only formulations, as studies using fish oil, which naturally contain both EPA and DHA, were shown to increase LDL cholesterol.6  This research demonstrates the powerful ability of EPA-only AlmegaPL® to outperform other omega-3 sources to support cardiovascular health.*The CEO of iwi life, Tom Dimke, responded to the results stating that 'integrating AlmegaPL® in iwi life products—an ingredient with such impressive clinical data supporting it—allows us to bring innovative and effective consumer-ready products to the market with confidence.'The triple patented microalgae technology of AlmegaPL® is the first and only commercially available photosynthetic source of long-chain omega fatty acids available for human consumption in the USA.

加努扎。”这项研究的重要性在现实世界的人群中得到了强调，这些人群主要是血脂正常的补充剂消费者。这突出表明，使用天然来源的AlmegaPL®海藻油作为非处方补充剂，有助于支持普通健康人群的心血管健康。”AlmegaPL®使用从光自养微藻Nannochloropsis中提取的专有ω-3脂肪酸菌株，目前两项独立研究已在临床上证实该菌株可将残余胆固醇降低高达25%。1,2两项研究均未导致LDL胆固醇升高，这是仅EPA制剂的独特益处，因为使用鱼油的研究，天然同时含有EPA和DHA，可增加低密度脂蛋白胆固醇。6这项研究表明，仅EPA的AlmegaPL®在支持心血管健康方面优于其他ω-3来源的强大能力。*iwi life首席执行官汤姆·戴姆克，回应结果称，“将AlmegaPL®整合到iwi life products中，这是一种具有如此令人印象深刻的临床数据支持的成分，使我们能够满怀信心地将创新有效的消费者就绪产品推向市场。”AlmegaPL®的三重专利微藻技术是美国第一个也是唯一一个可供人类食用的长链ω脂肪酸的商业光合来源。

The utilization of AlmegaPL® in .

AlmegaPL®在中的使用。

Rao et al., 2020 Nutrients.

Rao等人，2020年营养素。

Ganuza et al., 2024 Front Nutr.

Ganuza等人，2024 Front Nutr。

World Health Organization, 2021 Cardiovascular Diseases Fact Sheet.

世界卫生组织，2021年心血管疾病概况。

Micha, Renata et al., 2017 JAMA.

Micha，Renata等人，2017年《美国医学会杂志》。

Murphy R.A. et al.,  2015 Nutrients.

Murphy R.A.等人，2015年营养素。

Eslick et al., 2009 Int J Cardiol

Eslick等人，2009国际心脏病学杂志

Kagan et al., 2013 Lipids Health Dis.

Kagan等人，2013年脂质健康疾病。

SOURCE Qualitas Health (dba iwi life)

SOURCE Qualitas Health（dba iwi life）